Rosiptor

• Description :

  Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro[1][2].

• Product Name Alternative :

  AQX-1125

• UNSPSC :

  12352211

• Target :

  Phosphatase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Rosiptor.html

• Concentration :

  10mM

• Purity :

  99.73

• Solubility :

  DMSO : 150 mg/mL (ultrasonic; warming)

• Smiles :

  C[C@@]([C@H]1CO)(CC[C@H](O)C1)[C@](CC[C@@]2(C)[C@@]3([H])CCC2=C)([H])[C@H]3CN

• Molecular Formula :

  C20H35NO2

• Molecular Weight :

  321.50

• References & Citations :

  [1]Stenton GR, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013 Mar;168 (6) :1506-18.|[2]Cross J, et al. AQX-1125, small molecule SHIP1 activator inhibits NSC-125066-induced pulmonary fibrosis. Br J Pharmacol. 2017 Sep;174 (18) :3045-3057.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [782487-28-9]